Researchers at the Spanish National Cancer Research Center and the 12 de Octubre University Hospital in Madrid have developed a new immunotherapy to treat multiple myeloma that shows, in the laboratory, to be more effective than the immunotherapy currently used as preferred treatment.
Patient-Reported Outcomes of participants in the phase II/III QUILT 3.032 study of N-803 plus BCG in BCG-unresponsive non-muscle invasive bladder cancer were published by the peer-reviewed journal Urology Practice.
A diet that limits meat and dairy but is rich in fruits, vegetables, grains, and nuts is linked to less erectile dysfunction, urinary incontinence, and other common side effects seen in prostate cancer patients, a new study shows.
University of Florida College of Pharmacy researchers have pinpointed the genetic blueprints behind dolastatin 10, a marine natural product that has led to six FDA-approved cancer drugs since 2011.
Protecting free preventive cancer screenings and reducing the burden of medical debt are the top issues of concern for cancer patients and survivors today, according to a new survey by the American Cancer Society Cancer Action Network (ACS CAN) that asked participants to select their leading policy priorities for the year.
The phase III CheckMate -67T trial, evaluating the subcutaneous formulation of Opdivo (nivolumab) co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20) (herein referred to as “subcutaneous nivolumab”) compared to intravenous Opdivo in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior systemic therapy, demonstrated noninferiority for the co-primary endpoints of Cavgd28 (time-averaged Opdivo serum concentration over 28 days) and Cminss (trough serum concentration at steady state) compared to IV Opdivo.
The World Health Organization cancer agency, the International Agency for Research on Cancer, has released the latest estimates of the global burden of cancer.
Researchers have identified a next-generation BTK degrader that could help overcome treatment resistance in chronic lymphocytic leukemia and related blood cancers.
UCLA Health Jonsson Comprehensive Cancer Center researchers have identified a protein, UCHL1, in highly aggressive neuroendocrine carcinomas and neuroblastoma that could potentially be used as a molecular biomarker for diagnosing these cancers and predicting and monitoring responses to therapy.
Rice University researchers in the lab of chemist Han Xiao have identified a promising new immunological pathway to treat stubborn bone tumors, one of most prevalent forms of metastases in breast cancer patients.
